Literature DB >> 29052747

Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.

Altan F Ahmed1, Naziya Samreen2,3, Joseph R Grajo2, Ivan Zendejas4, Chris L Sistrom2, Amy Collinsworth5, Ashwini Esnakula5, Jehan L Shah2, Roniel Cabrera6, Brian S Geller2, Beau B Toskich2,7.   

Abstract

PURPOSE: To assess the radiopathologic correlation following Yttrium-90 transarterial radioembolization (TARE) of hepatocellular carcinoma (HCC) using variable radiodosimetry to identify imaging surrogates of histologic response.
METHODS: Twelve patients with HCC underwent ablative (≥ 190 Gy) and/or non-ablative (< 190 Gy) TARE delivered in a segmental, lobar, or combined fashion as a surgical neoadjuvant or bridge to transplantation. Both targeted tumor and treatment angiosome were analyzed before and after TARE utilizing hepatocyte-specific contrast-enhanced MRI or contrast-enhanced CT. Responses were graded using EASL and mRECIST criteria. Histologic findings including percent tumor necrosis and adjacent hepatic substrate effects were correlated with imaging features.
RESULTS: Complete pathologic necrosis (CPN) was observed in 7/12 tumors post-TARE. Ablative and non-ablative dosing resulted in CPN in 5/6 and 2/6 tumors, respectively. Hyperintensity on T2-weighted imaging, the absence of hepatocyte-specific gadolinium contrast uptake, and plateau or persistent enhancement kinetics in the angiosome correlated with CPN and performed similarly to EASL and mRECIST criteria in predicting CPN.
CONCLUSIONS: The absence of hepatocyte-specific contrast uptake, increased signal on T2-weighted sequences, and plateau or persistent enhancement in the angiosome may represent MRI surrogates of CPN following TARE of HCC. These findings correlated with EASL and mRECIST response criteria. Further investigation is needed to determine the role of these findings as possible adjuncts to conventional imaging criteria.

Entities:  

Keywords:  Hepatocellular carcinoma; Pathologic correlation; Radioembolization; Yttrium-90

Mesh:

Substances:

Year:  2018        PMID: 29052747     DOI: 10.1007/s00261-017-1354-6

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  3 in total

1.  Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.

Authors:  Andrew C Gordon; Ahmed Gabr; Ahsun Riaz; Omar M Uddin; Nadine Abouchaleh; Rehan Ali; Joseph Kallini; Riad Salem; Robert J Lewandowski
Journal:  Cardiovasc Intervent Radiol       Date:  2018-06-12       Impact factor: 2.740

Review 2.  Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum.

Authors:  Zlatko Devcic; Mohamed Elboraey; Lucas Vidal; Kabir Mody; Denise Harnois; Tushar Patel; Beau B Toskich
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

3.  The use of neoadjuvant lobar radioembolization prior to major hepatic resection for malignancy results in a low rate of post hepatectomy liver failure.

Authors:  Altan Ahmed; John A Stauffer; Jordan D LeGout; Justin Burns; Kristopher Croome; Ricardo Paz-Fumagalli; Gregory Frey; Beau Toskich
Journal:  J Gastrointest Oncol       Date:  2021-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.